Viewing data from:

HYDROCORTISONE VALERATE

ANDA

HYDROCORTISONE VALERATE | A074489 | COSETTE PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Hydrocortisone Valerate (2023)

Total Spending

$2.1M

Total Claims

25,162

Beneficiaries

15,376

Avg Cost/Unit

$1.57

Spending Trend

$8.7M(2019)→$4.9M(2020)→$4.0M(2021)→$3.5M(2022)→$2.1M(2023)

YoY Change:-14.9%

5yr CAGR:-7.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs1 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

LUPIN LTDHYDROCORTISONE VALERATE USP

DMF 311432016

SYMBIOTICA SPECIALITY INGREDIENTS SDN BHDHYDROCORTISONE VALERATE USP

DMF 314232017

TRIFARMA SPAHYDROCORTISONE VALERATE

DMF 333342018

YANGZHOU PHARMACEUTICAL CO LTDInactiveHYDROCORTISONE VALERATE USP

DMF 309712016

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Aug 12, 1998	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.2%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Aug 12, 1998

No patent or exclusivity listings for this strength.